Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin

Inclusion Criteria:

* • Histologically confirmed diagnosis of skin melanoma (stages I-IV according to TNM classification)

  * Underwent complete surgical resection of primary tumor with negative margins
  * Age 18 years or older
  * Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  * Life expectancy of at least 6 months
  * Adequate bone marrow function: absolute neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 90 g/L
  * Adequate hepatic function: bilirubin ≤ 1.5 × upper limit of normal (ULN), transaminases ≤ 2.5 × ULN
  * Adequate renal function: creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min
  * Willing and able to provide written informed consent
  * Willing to comply with study procedures and follow-up schedule

Exclusion Criteria:

* • Presence of distant metastases at the time of diagnosis (except for stage IV patients included per protocol)

  * Prior immunotherapy, chemotherapy, or radiotherapy for melanoma
  * History of other malignant neoplasms within the past 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix)
  * Severe or uncontrolled organ dysfunction (cardiac, hepatic, renal, pulmonary)
  * Active infection requiring systemic therapy
  * Known hypersensitivity to interferon-alpha or any study medications
  * Known hypersensitivity to dacarbazine, cisplatin, or any excipients
  * Pregnancy or breastfeeding
  * Psychiatric or cognitive impairment that would interfere with study participation
  * Participation in another interventional clinical trial within 30 days prior to enrollment
  * Any condition that, in the investigator's opinion, would compromise participant safety or interfere with study objectives